Article Versions Notes

Yano Y, Ohno T, Komura K, Fukuokaya W, Uchimoto T, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Yamazaki S, et al. Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. Cancers. 2022; 14(22):5659. https://doi.org/10.3390/cancers14225659

Yano, Yusuke, Takaya Ohno, Kazumasa Komura, Wataru Fukuokaya, Taizo Uchimoto, Takahiro Adachi, Yosuke Hirasawa, Takeshi Hashimoto, Atsuhiko Yoshizawa, Shogo Yamazaki, and et al. 2022. "Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab" Cancers 14, no. 22: 5659. https://doi.org/10.3390/cancers14225659

Yano, Y., Ohno, T., Komura, K., Fukuokaya, W., Uchimoto, T., Adachi, T., Hirasawa, Y., Hashimoto, T., Yoshizawa, A., Yamazaki, S., Tokushige, S., Nishimura, K., Tsujino, T., Nakamori, K., Yamamoto, S., Iwatani, K., Urabe, F., Mori, K., Yanagisawa, T., ... Azuma, H. (2022). Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab. Cancers, 14(22), 5659. https://doi.org/10.3390/cancers14225659